Metabolic effects of treatment with atypical antipsychotics.
Kane
John M
JM
Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Barrett
Eugene J
EJ
Casey
Daniel E
DE
Correll
Christoph U
CU
Gelenberg
Alan J
AJ
Klein
Samuel
S
Newcomer
John W
JW
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002648:Child; D003245:Consensus Statements as Topic; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000453:epidemiology / Q000378:metabolism; D004348:Drug Labeling / Q000592:standards; D004502:Education, Medical, Continuing; D006306:Health Surveys; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced* / Q000453:epidemiology / Q000378:metabolism; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology / Q000378:metabolism; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011618:Psychotic Disorders / Q000188:drug therapy / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D014150:Antipsychotic Agents